Iron deficient erythropoiesis might play key role in development of anemia in cancer patients

被引:16
|
作者
Park, Silvia [1 ]
Jung, Chul Won [1 ]
Kim, Kihyun [1 ]
Kim, Seok Jin [1 ]
Kim, Won Seog [1 ]
Jang, Jun Ho [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
关键词
cancer; anemia; soluble transferrin receptor; hepcidin; SERUM TRANSFERRIN RECEPTOR; CHRONIC HEART-FAILURE; BINDING-CAPACITY; DARBEPOETIN ALPHA; INTRAVENOUS IRON; EPOETIN-ALPHA; DOUBLE-BLIND; CHEMOTHERAPY; PREVALENCE; MANAGEMENT;
D O I
10.18632/oncotarget.5658
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Multifactorial pathogenesis is involved in anemia of cancer patients and defining the causes of anemia is not always simple. Methods: The incidence of anemia among 4 major cancers (gastric, colorectal, lung cancer and hepatocellular carcinoma), and biochemical features of anemia using ferritin, CRP, hepcidin and soluble transferrin receptor (sTfR) were assessed. Anemia was defined either by hemoglobin (Hb) <= 11 g/dL or a drop of Hb 2 g/dL or more during anticancer treatment. Results: Among the 345 patients including 152 lung cancer, 101 gastric cancer, 69 colorectal cancer and 23 hepatocellular carcinoma, 49 patients (14.2%) had anemia at their initial diagnosis of cancer. During treatment, 129 (37.4%) experienced anemia, and 34 (26.4%) were treated mostly by transfusion. Biochemical feature of anemia was examined with 39 patients' samples. When comparing to the reference value from general population, cancer patients showed numerically higher ferritin, sTfR, CRP and hepcidin level. Among the cancer patients, anemic patients had significantly higher ferritin (p = 0.050) and sTfR (p = 0.009) level compared to non-anemic patients. Conclusion: Anemia is a common issue in cancer patients and is largely undertreated with sub-optimal diagnoses of cause. The rates of anemia increase significantly during anti-cancer treatment and appear to be largely associated with iron deficiency.
引用
收藏
页码:42803 / 42812
页数:10
相关论文
共 50 条
  • [1] Thrombosis with erythropoietic stimulating agents - Does iron-deficient erythropoiesis play a role?
    Dahl, Naomi V.
    Henry, David H.
    Coyne, Daniel W.
    SEMINARS IN DIALYSIS, 2008, 21 (03) : 210 - 211
  • [2] METABOLISM OF ERYTHROPOIETIN IN PATIENTS WITH ANEMIA DUE TO DEFICIENT ERYTHROPOIESIS
    ROSSE, WF
    WALDMANN, TA
    JOURNAL OF CLINICAL INVESTIGATION, 1964, 43 (07): : 1348 - &
  • [3] The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents
    Mhaskar, Rahul
    Wao, Hesborn
    Miladinovic, Branko
    Kumar, Ambuj
    Djulbegovic, Benjamin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [4] ROLE OF IRON ON ERYTHROPOIESIS IN IRON-DEFICIENT AND IRON-OVERLOADED STATE
    LUTTON, JD
    IBRAHAM, NG
    HOFFSTEIN, S
    LEVERE, RD
    FEDERATION PROCEEDINGS, 1984, 43 (03) : 614 - 614
  • [5] ERYTHROPOIESIS CONTROL IN PATIENTS WITH IRON-DEFICIENCY ANEMIA
    GUDIM, VI
    EREMENKO, LL
    IVANOVA, VS
    GNATYUK, AG
    KOTELNIKOV, VM
    DYAGELEVA, OA
    TOKAREV, YN
    KOZINETS, GI
    MITEREV, YG
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1991, 36 (07): : 3 - 5
  • [6] Iron Deficiency and Anemia in Cancer Patients: The Role of Iron Treatment in Anemic Cancer Patients
    Abiri, Behnaz
    Vafa, Mohammadreza
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2020, 72 (05): : 864 - 872
  • [7] Is intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?
    Bohlius, Julia
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 688 - 689
  • [8] Is intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?
    Julia Bohlius
    Nature Clinical Practice Oncology, 2008, 5 : 688 - 689
  • [9] Deformation sensors might play a key role in stereokinetic phenomena
    van de Grind, W. A.
    PERCEPTION, 2007, 36 : 98 - 98
  • [10] The role of intravenous iron in the treatment of anemia in cancer patients
    Steinmetz, H. Tilman
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (03) : 177 - 191